Prostatype Genomics AB (publ)'s latest marketcap:
As of 06/25/2025, Prostatype Genomics AB (publ)'s market capitalization has reached $4.45 M. According to our data, Prostatype Genomics AB (publ) is the 43837th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.45 M |
| Revenue (ttm) | 200,431 |
| Net Income (ttm) | -4,289,829.5 |
| Shares Out | 34.18 M |
| EPS (ttm) | -3.04 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/23/2025 |
Prostatype Genomics AB (publ)'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/25/2025 | kr4.45 M | -34.33% | 43837 |
| 12/30/2024 | kr74.42 M | 555.78% | 39785 |
| 12/29/2023 | kr11.35 M | -76.58% | 42557 |
| 12/30/2022 | kr48.46 M | -64.07% | 38514 |
| 12/30/2021 | kr134.89 M | -28.46% | 34080 |
| 12/30/2020 | kr188.56 M | 28903 |
Company Profile
About Prostatype Genomics AB
Prostatype Genomics AB is a biotechnology company specializing in the development and commercialization of advanced prognostic gene tests for prostate cancer.
Key Products & Services
- Prostatype Test System: A cutting-edge diagnostic tool that integrates gene expression data with clinical parameters, including PSA levels, Gleason Score, and Tumor Stage, to generate a precise P-score.
- Decision Support: Provides actionable insights for both patients and physicians to guide personalized treatment strategies.
Technology & Research
The company's proprietary test leverages a comprehensive database of prostate cancer patient data, ensuring high accuracy and reliability in prognostic assessments.
Company Background
Founded in 2007 and headquartered in Solna, Sweden, Prostatype Genomics AB (publ) is committed to advancing precision medicine in oncology.
Frequently Asked Questions
-
What is Prostatype Genomics AB (publ)'s (STO-PROGEN) current market cap?As of 06/25/2025, Prostatype Genomics AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $4.45 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Prostatype Genomics AB (publ) (STO-PROGEN) rank globally by market cap?Prostatype Genomics AB (publ) global market capitalization ranking is approximately 43837 as of 06/25/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.